证券代码：301087 证券简称：可孚医疗 可孚医疗科技股份有限公司 投资者关系活动记录表 编号：2023-004 投资者关系活动类 别 特定对象调研 □分析师会议 □媒体采访 业绩说明会 □新闻发布会 □路演活动 现场参观 其他 参与单位名称及人 员姓名 公司 2022 年度业绩说明会采用网络远程方式进行，面向全体投资者 时间 2023-5-11 地点 可孚医疗会议室 上市公司接待人员 姓名 董事长/总裁张敏；董事/副总裁/董事会秘书薛小桥；副总裁/财务总监陈望朋； 独立董事刘爱明；保荐代表人邹扬 投资者关系活动主 要内容介绍 1、请问下公司未来发展规划是什么？ 答：尊敬的投资者，您好！公司始终秉承"健康守护，关爱一生"的企业 宗旨，构建了覆盖各年龄层、全部消费群体的产品体系，致力于为用户提供终 身信赖的医疗健康产品和一站式解决方案，积极践行"健康中国战略"，为保 障人民群众健康安全、推动中国医疗器械产业的发展和提升中国医疗器械企业 在全球的地位而持续努力。 公司将研发创新作为推动持续发展的动力，基于积 累的良好研发基础，致力于新产品、新技术的创新突破以及现有产品技术升级， 开发满足消费者需求、具有更高科技 ...

可孚医疗科技股份有限公司2022年年度报告全文 可孚医疗科技股份有限公司 2022 年年度报告 2023-021 ...

Financial Performance - The company's revenue for Q1 2023 reached ¥855,367,818.78, representing a 42.38% increase compared to ¥600,753,831.09 in the same period last year[5] - Net profit attributable to shareholders was ¥134,514,033.42, a significant increase of 167.93% from ¥50,204,732.44 year-on-year[5] - The basic earnings per share rose to ¥0.65, up 170.83% from ¥0.31 in the previous year[5] - Operating profit for Q1 2023 was ¥157,563,269.47, compared to ¥59,566,256.94 in Q1 2022, reflecting a growth of 164.6%[23] - Net profit for Q1 2023 amounted to ¥155,540,561.37, a substantial increase from ¥58,840,441.70 in the previous year[23] - The net profit for Q1 2023 was CNY 133,373,483.95, a significant increase of 153% compared to CNY 52,632,513.24 in the same period last year[25] - Basic and diluted earnings per share for Q1 2023 were both CNY 0.65, up from CNY 0.24 in Q1 2022, representing a 171% increase[25] Cash Flow and Liquidity - Operating cash flow improved to ¥154,022,832.30, a turnaround from a negative cash flow of ¥317,768,933.80 in the same period last year, marking a 148.47% increase[5] - The net cash flow from operating activities was ¥154,022,832.30, a significant improvement from the previous period's negative cash flow of -¥317,768,933.80, representing a change of -148.47% due to reduced payments to suppliers and increased sales collections[14] - Cash flow from operating activities generated a net cash inflow of CNY 154,022,832.30, compared to a net outflow of CNY 317,768,933.80 in the previous year[28] - Cash and cash equivalents at the end of the period were ¥1,417,777,818.28, slightly down from ¥1,449,959,044.04 at the beginning of the year[22] - Cash and cash equivalents at the end of Q1 2023 were CNY 1,320,497,604.99, down from CNY 1,730,252,830.26 at the end of Q1 2022[29] Expenses and Costs - Total operating costs for Q1 2023 were ¥676,950,984.19, up 26.3% from ¥536,028,236.07 in Q1 2022[23] - Research and development expenses increased by 39.82% to ¥29,501,924.78, reflecting higher personnel costs and material expenses[13] - The company reported a significant increase in research and development expenses, which rose to ¥29,501,924.78 from ¥21,100,488.96, marking an increase of 39.6%[23] - The company reported a 57.12% increase in sales expenses, totaling ¥195,901,260.69, due to higher service fees and marketing costs[13] Assets and Liabilities - The company's total assets at the end of Q1 2023 were ¥6,360,300,564.21, a slight decrease of 0.79% from ¥6,410,837,630.17 at the end of the previous year[5] - Total assets decreased to ¥6,360,300,564.21 from ¥6,410,837,630.17, a decline of 0.8%[22] - Total liabilities decreased to ¥1,326,522,271.57 from ¥1,377,934,885.05, a reduction of 3.7%[22] - The company experienced a 253.00% increase in long-term borrowings, reaching ¥106,000,000.00, primarily due to new loans taken during the period[11] Shareholder Information and Repurchase Plans - As of the end of the reporting period, the total number of ordinary shareholders was 23,304, with no preferred shareholders[16] - The largest shareholder, Changsha Medical Investment Co., Ltd., holds 40.81% of the shares, amounting to 85,079,923 shares, with 23,010,000 shares pledged[16] - The company plans to repurchase shares using self-owned funds, with a total repurchase amount not less than ¥100 million and not exceeding ¥200 million, at a price not exceeding ¥60.00 per share[18] - As of March 31, 2023, the company had repurchased a total of 3,680,769 shares, representing 1.77% of the total share capital, with a total transaction amount of ¥136,317,242.94[19] - The highest repurchase price was ¥37.94 per share, while the lowest was ¥36.00 per share[19] - The company is focused on implementing an employee stock ownership plan or equity incentive through the repurchased shares[18] Strategic Focus - The report indicates a strategic focus on improving cash flow management and shareholder value through share repurchases and operational efficiency[14] - The company plans to continue expanding its market presence and investing in new product development to drive future growth[23] Other Financial Metrics - The company's weighted average return on equity improved to 2.69%, an increase of 1.68 percentage points from the previous year[5] - The impact of exchange rate fluctuations on cash and cash equivalents was -¥85,583.07, which is a 634.04% increase from -¥11,659.26 in the previous period, attributed to increased exchange rate volatility[14] - The company reported a total cash outflow from financing activities of CNY 413,806,436.72, compared to CNY 240,826,576.86 in the previous year[29] - The net cash flow from investing activities was negative CNY 115,099,925.82, an improvement from negative CNY 163,099,190.61 in the same period last year[28] - The company received CNY 324,848,762.14 in cash from borrowings during Q1 2023, compared to CNY 498,163,187.40 in the previous year[28] - The report for Q1 2023 was not audited[30]

编号：2021-006 证券代码：301087 证券简称：可孚医疗 可孚医疗科技股份有限公司 投资者关系活动记录表 | --- | --- | --- | |-----------------------|----------------------------------------------------------------------|------------------------------------------------------------------------| | 投资者关系活动类别 | □特定对象调研 \n□媒体采访 \n□新闻发布会 \n□现场参观 \n☑其他 电话会议 | □分析师会议 \n □业绩说明会 \n □路演活动 \n | | 参与单位名称及人员 | | 富国基金孙笑悦、蒲世林；安信基金池陈森；乘安资管王镜程；东证资管周琰； | | 姓名 | | 中海基金梁静静；东方基金蔡尚军；东吴自营于彦秋；工银瑞信基金李乾宁； | | | | 广发基金王琪；大成基金邹建、杨挺、陈泉龙、戴军；光大永明资产王申璐； | | | | 国寿安保基金祁善斌；泓澄投资樊翔宇；弘毅远方基金 ...

编号：2021-004 证券代码：301087 证券简称：可孚医疗 可孚医疗科技股份有限公司 投资者关系活动记录表 | --- | --- | --- | |--------------------|--------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------| | | | | | 投资者关系活动类别 | 特定对象调研 | □分析师会议 | | | □媒体采访 | □业绩说明会 | | | □新闻发布会 | □路演活动 | | | 现场参观 | | | | □其他 | （请文字说明其他活动内容） | | 参与单位名称及人员 | | 中信证券甘坛焕、李芳、蒋鹏飞、覃文斌；万泰华瑞陈辉斌；邕兴投资刘佳琪、 | | 姓名 | | 周炼；轻盐创投曾续娣；迪策投资张擎柱；源乘投资邬安莎；泽源基金谢文； | | | | 南方基金秦乾一、郑 ...

编号：2021-003 证券代码：301087 证券简称：可孚医疗 可孚医疗科技股份有限公司 投资者关系活动记录表 | --- | --- | --- | |-----------------------------|--------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ...

编号：2021-005 证券代码：301087 证券简称：可孚医疗 可孚医疗科技股份有限公司 投资者关系活动记录表 | --- | --- | --- | |-----------------------------|-----------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------| | 投资者关系活动类别 | ☑ 特定对象调研 \n□媒体采访 \n□新闻发布会 \n□现场参观 \n☑其他 电话会议 | □分析师会议 \n □业绩说明会 \n □路演活动 \n | | 参与单位名称及人员 | | 广发证券罗佳荣、漆经纬、朱新彦；长城基金谭小兵、陈蔚丰 ...